300+ investors in your industry, stage, and region Get
Any industry
Community
Proptech
Biotech
Climate
Artificial Intelligence
Media (Entertainment)
Impact
FinTech
Marketplace
EdTech
Consumer
Agriculture (AgTech)
Web3
Clean Energy
B2B
Organic Food
Big Data
Video Games
Payments
Celebrity
Franchise
Mobile
Local
Social Network
Platforms
Crowdfunding
CleanTech
Film
Theatre
Life Science
Non Profit
Transportation
Gaming
Energy
Hardware
Health Care
Enterprise
Sustainability
Venture Capital
Restaurants
Fashion
Real Estate
Retail
Infrastructure
Mobile Apps
Beauty
LGBT
Publishing
Sporting Goods
Oil and Gas
Education
Renewable Energy
Food and Beverage
Cryptocurrency
Finance
Financial Services
Photography
Art
Medical
Digital Media
Music
Internet
Social Media
Manufacturing
Facebook
Blockchain
Legal
Android
Social Impact
Google
Construction
Sports
eSports
Enterprise Software
Email
Wellness
Hospitality
Travel
Fitness
Mobile Advertising
Cannabis
Recruiting
Biotechnology
Medical Device
Wine and Spirits
Automotive
Social
InsurTech
SaaS
Software
Any country
Qatar
South Korea
Africa
Asia
LATAM
Europe
Oceania
Middle East
Ireland
Singapore
Indonesia
Spain
Saudi Arabia
Belarus
Belgium
Colombia
Denmark
Ecuador
Czech Republic
Estonia
Ghana
Ethiopia
Finland
Barbados
Italy
Jersey
Cayman Islands
Mali
Malaysia
Mauritius
Poland
Rwanda
Togo
Slovenia
San Marino
Tanzania
Thailand
Uruguay
Venezuela
Portugal
Azerbaijan
Namibia
Bolivia
Latvia
Cyprus
New Zealand
United States
Germany
Australia
India
United Kingdom
Canada
China
South Africa
Brazil
Japan
Sri Lanka
Vietnam
Argentina
Armenia
Austria
Bangladesh
Bahrain
Bulgaria
Bermuda
Chile
Cameroon
Switzerland
Belize
Costa Rica
Algeria
Georgia
Egypt
Hong Kong
Gibraltar
Faroe Islands
Greece
Croatia
France
Hungary
Kuwait
Israel
Lebanon
Cambodia
Kenya
Jordan
Lithuania
Liberia
Liechtenstein
Myanmar
Kazakhstan
Morocco
Norway
Mexico
Panama
Malta
Peru
Philippines
Nicaragua
Pakistan
Russian Federation
Romania
Sweden
Serbia
Seychelles
Turkey
Puerto Rico
Sierra Leone
Senegal
Tunisia
Tajikistan
El Salvador
Uganda
Zambia
Uzbekistan
Taiwan
Ukraine
Zimbabwe
Bahamas
Guatemala
Iraq
Iceland
Nigeria
United Arab Emirates
Honduras
Isle of Man
Luxembourg
Oman
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Biotechnology VC Funds & Investors in China (May 2026)

The most active venture capital funds investing in China Biotechnology startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in China Biotechnology startup companies. Find investors to raise a Series A, Series B or Series C round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
Qiming Venture Partners
VC Fund
36 China, United States, Hong Kong Series B, Series A, Series C Health Care, Medical, Biotechnology $4.1M–$148M
Sequoia Capital China
VC Fund
34 China, United States, Australia Series A, Series B, Series C Health Care, Biotechnology, Artificial Intelligence $4M–$200M
Lilly Asia Ventures
VC Fund
24 China, United States, Hong Kong Series A, Series B, Series C Biotechnology, Health Care, Medical $11M–$275M
Kaitai Capital
VC Fund
20 China, United States Series A, Angel, Seed Biotechnology, Health Care, Pharmaceutical $412k–$21M
Sherpa Venture Capital
VC Fund
18 China, United States, Kenya Series A, Series B, Series C Biotechnology, Health Care, Medical $6.9M–$151M
IDG Capital
VC Fund
18 China, United States, India Series A, Series B, Series C Software, Internet, E-Commerce $2.9M–$190M
Hillhouse Capital Group
VC Fund
17 China, United States, India Series B, Series A, Series C Biotechnology, Health Care, Software $1.4M–$310M
Med-Fine Capital
VC Fund
16 China, United States Series A, Series B, Seed Health Care, Biotechnology, Medical $2.7M–$50M
Frees Fund
VC Fund
15 China, United States, Singapore Series A, Seed, Angel Artificial Intelligence, E-Commerce, Health Care $412k–$28M
Legend Capital
VC Fund
15 China, United States, South Korea Series B, Series A, Series C Health Care, Biotechnology, Medical $2.7M–$200M
Northern Light Venture Capital
VC Fund
15 China, United States, South Korea Series A, Series B, Seed Health Care, Medical, Internet $500k–$58M
TF Capital
VC Fund
14 China, United States Series A, Series B, Seed Biotechnology, Health Care, Pharmaceutical $10M–$120M
BioVenture
VC Fund
13 China, United States, Taiwan Series A, Series B, Series C Health Care, Medical, Biotechnology $2.7M–$58M
Highlight Capital
VC Fund
13 China, United States, Portugal Series A, Series B, Series C Health Care, Biotechnology, Medical $2.7M–$200M
CDH Investments
VC Fund
11 China, United States, Canada Series A, Series B, Series C Manufacturing, Biotechnology, Health Care $6.9M–$300M
CD Capital
VC Fund
10 China, United States Series A, Series B, Angel Health Care, Biotechnology, Medical Device $412k–$34M
Green Pine Capital Partners
VC Fund
10 China, United States, Canada Series A, Angel, Series B Artificial Intelligence, Manufacturing, Software $412k–$150M
Addor Capital
VC Fund
10 China, Hong Kong, United States Series A, Series B Manufacturing, Medical, Electronics $1.4M–$41M
Puhua Capital
VC Fund
10 China, United Kingdom, United States Series A, Series B, Angel Health Care, Medical, Biotechnology $412k–$69M
ZhenFund
VC Fund
9 China, United States, Singapore Series A, Seed, Series B Artificial Intelligence, Software, E-Commerce $820k–$50M
Gaorong Capital
VC Fund
9 China, United States, Hong Kong Series A, Series B, Series C Software, E-Commerce, Information Technology $2.7M–$500M
LYFE Capital
VC Fund
9 China, United States, France Series A, Series B, Series C Health Care, Biotechnology, Medical $8.2M–$200M
K2VC
VC Fund
9 China, United States, Japan Series A, Angel, Seed E-Commerce, Health Care, Software $412k–$23M
Cowin Capital
VC Fund
9 China, Hong Kong, United States Series A, Series B, Series C Manufacturing, Health Care, Software $4.1M–$100M
EFung Capital
VC Fund
8 China, United States, India Series A, Series B, Series C Biotechnology, Health Care, Pharmaceutical $1.4M–$84M
Cowin Venture
VC Fund
8 China, United States, Canada Series A, Series B, Angel Biotechnology, Health Care, Medical $412k–$83M
Baidu Ventures
VC Fund
8 China, United States, Germany Series A, Seed, Series B Artificial Intelligence, Health Care, Biotechnology $1.3M–$64M
Source Code Capital
VC Fund
8 China, United States, Spain Series B, Series A, Series C Software, E-Commerce, Artificial Intelligence $1.4M–$200M
Volcanics Venture
VC Fund
8 China, United States Series A, Series B, Seed Health Care, Biotechnology, Software $350k–$30M
Lapam Capital
VC Fund
8 China, United States Series B, Series A, Series C Biotechnology, Pharmaceutical, Health Care $12M–$100M
Legend Star
VC Fund
8 China, United States, France Series A, Angel, Seed Health Care, Medical, Biotechnology $412k–$30M
Oriental Fortune Capital
VC Fund
8 China, United States Series A, Series B, Seed Software, Information Technology, E-Commerce $412k–$100M
Huagai Capital
VC Fund
8 China, United States, Hong Kong Series A, Series B, Angel Health Care, Biotechnology, Medical $412k–$90M
Prox Ventures
VC Fund
7 China, United States, United Kingdom Seed, Series A Medical, Biotechnology, Health Care
Redhill Capital
VC Fund
7 China Seed, Series A Health Care, Medical, Medical Device $1.4M–$24M
CASH Capital
VC Fund
7 China, United States Series A, Series B, Series C Health Care, Biotechnology, Manufacturing $1.4M–$151M
Lucion
VC Fund
7 China Series A, Seed, Series B Biotechnology, Medical, Manufacturing $1.4M–$522M
Empower Investment
VC Fund
7 China, United States, India Angel, Series A, Seed Information Technology, Artificial Intelligence, Health Care $137k–$11M
BioTrack Capital
VC Fund
7 China, United States, Singapore Series A, Series B, Seed Health Care, Biotechnology, Medical
Shenzhen Capital Group
VC Fund
7 China, United States, Japan Series A, Series B, Series C Manufacturing, Health Care, Software $1.4M–$604M
China Growth Capital | CGC
VC Fund
6 China, United States, Hong Kong Series A, Series B, Seed Software, Information Technology, E-Commerce $412k–$41M
BVCF
VC Fund
6 China, United States, Germany Series A, Series B, Series C Biotechnology, Health Care, Pharmaceutical $6.8M–$325M
F-Prime Capital
VC Fund
6 United States, United Kingdom, China Series A, Series B, Series C Health Care, Biotechnology, Medical $5M–$135M
Delian Capital
VC Fund
6 China, United States, France Series A, Series B, Seed Biotechnology, Health Care, Manufacturing $1.6M–$27M
SDIC Venture Capital
VC Fund
6 China, United States, Hong Kong Series B, Series A, Series C Manufacturing, Biotechnology, Health Care $2.7M–$275M
Linear Capital
VC Fund
6 China Seed, Series A, Angel Biotechnology, Artificial Intelligence, Robotics $1.4M–$10M
Lotus Lake Ventures
VC Fund
6 China Series A, Series B, Series C Biotechnology, Health Care, Pharmaceutical $687k–$69M
Oriza Holdings
VC Fund
6 China, United States, Canada Series A, Series B, Series C Health Care, Biotechnology, Manufacturing $1.4M–$300M
Decheng Capital
VC Fund
6 United States, China, Canada Series B, Series A, Series C Biotechnology, Health Care, Medical $8M–$121M
SBCVC
VC Fund
6 China, United States, Australia Series B, Series A, Series C Health Care, Software, Information Technology $2M–$100M
Access all 1526 VC funds in China Biotechnology startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

Qiming Venture Partners
VC Fund · Shanghai, Shanghai, China · 36 investments in China Biotechnology startups, 59 in the past 12 months

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised. Since our establishment, we have investedin outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 480 fast-growing and innovative companies. Over 180 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange or Shenzhen Stock Exchange, or through M&A or by other means. There are also over 70 portfolio companies that have achieved unicorn status.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 487
  • Round size: Series A $4.1M–$48M; Series B $10M–$100M; Series C $16M–$148M
  • Lead/follow: 47% lead, 53% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Atantares — We are a development stage startup enabling the next generation of precision medicine by fusing biochip and AI technologies.
  • Saints Sages Medical — Saints Sages Medical is engaged in the production and sales of minimally invasive surgical medical devices. They have several energy device products that are widely used in minimally invasive surgery, hepatobiliary surgery, gynecology, urology, thoracic surgery, and other departments. Saints Sages closely monitors clinical needs and develops moreinnovative minimally invasive surgical devices to serve global patients, relying on a professional research and development team and years of the clinical transformation experience.
  • Epigenic Therapeutics — Epigenic Therapeutics is a biotech firm that offers gene editing therapy.
Show all investments...

Sequoia Capital China
VC Fund · Beijing, Beijing, China · 34 investments in China Biotechnology startups, 56 in the past 12 months

We help founders build enduring companies.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Artificial Intelligence
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Australia

Investor stats

  • Total investments: 643
  • Round size: Series A $4M–$90M; Series B $11M–$172M; Series C $25M–$200M
  • Lead/follow: 42% lead, 58% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • FUE Bioscience — FUE Bioscience is a medical robot R&D business that specializes in microsurgery above the head and neck. It continues to develop a product matrix of fully intelligent, high-precision, and anthropomorphic surgical robots based on the platform of macro-micro-controlled humanoid dual-arm robots.
  • Life Wilderness — Life Wilderness reimagines human-computer interaction and is linked to the transportation and travel industries.
  • Xintu Heterogeneous — Xintu Heterogeneous offers data storage solutions for heterogeneous computing.
Show all investments...

Lilly Asia Ventures
VC Fund · Shanghai, Shanghai, China · 24 investments in China Biotechnology startups, 21 in the past 12 months

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 163
  • Round size: Series A $11M–$69M; Series B $21M–$100M; Series C $27M–$275M
  • Lead/follow: 26% lead, 74% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Akura Medical — Akura Medical is developing a next-generation thrombectomy device that aims to simplify thrombectomy through an easy-to-use, single-pass procedure that efficiently removes blood clots.
  • Precede Biosciences — Precede Biosciences is revolutionizing precision medicine by revealing unprecedented insights into disease-defining biology from a simple blood test. Discover how we are helping create a world where medicine is developed more successfully, and every diagnosis is precise and minimally invasive.
  • LYNK Pharmaceuticals — LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.
Show all investments...

Kaitai Capital
VC Fund · Hangzhou, Zhejiang, China · 20 investments in China Biotechnology startups

KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series A, Angel, Seed
  • Geography: China, United States

Investor stats

  • Total investments: 93
  • Round size: Seed $1.4M–$20M; Angel $412k–$14M; Series A $1.4M–$21M
  • Lead/follow: 35% lead, 65% follow

Portfolio highlights

  • Levinthal — Levinthal is an AI-driven protein design platform. They offer services for artificial intelligence in food safety and medical care. They offer synthetic biology, food, feed, and environmental protection.
  • Huaboron Neutron — Huaboron Neutron is a biotechnology company that develops boron drugs and boron neutron capture therapy devices for the diagnosis of malignant cancers.
  • Nafi Pharmaceuticals — Nafi Pharmaceuticals develops novel medications for central nervous system illnesses.
Show all investments...

Sherpa Venture Capital
VC Fund · Beijing, Beijing, China · 18 investments in China Biotechnology startups

Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Kenya

Investor stats

  • Total investments: 64
  • Round size: Series A $6.9M–$38M; Series B $14M–$74M; Series C $19M–$151M
  • Lead/follow: 30% lead, 70% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • New Vision Medical — New Vision Medical is an IT infrastructure service provider that offers clinical trial-related digital platforms and services.
  • Leadsynbio — Pilot Bio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzymeengineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.
  • Danking Pharmaceuticals — Danking Medicine is an innovation-driven drug developer.
Show all investments...

IDG Capital
VC Fund · Beijing, Beijing, China · 18 investments in China Biotechnology startups, 24 in the past 12 months

IDG Capital is an investment firm that funds early- to growth-stage companies in the technology sector. Today they work with private equity and venture capital fund managers, investment advisors, and business entities from around the world. Their limited partners include many internationally reputable investors, including sovereign wealth funds,pension funds, institutional investors, major charities, university endowments, family offices, and business luminaries.IDG Capital brings a powerful combination of global perspective and local experience to investment management. As long-term value investors, they are highly skilled at mobilizing global resources to address local needs, especially for Inbound and outbound opportunities in China and the rest of Asia. Their highly skilled team has an in-depth understanding of the Chinese market and enjoys close relationships with many influential business leaders.

Show more...

Investment focus

  • Industry: Software, Internet, E-Commerce
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, India

Investor stats

  • Total investments: 611
  • Round size: Series A $2.9M–$100M; Series B $6.9M–$137M; Series C $15M–$190M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: May invest from a new fund soon — last raise in 2017

Portfolio highlights

  • Infinimos — Infinimos is a Cosmos ecological liquid staking derivatives platform that aims to build a decentralized and democratized ecosystem capable of maximizing staking rewards while retaining liquidity.
  • Xbotspace — Xbotspace is the generative AI middleware startup investigates the implementation and deployment of huge language models.
  • Biotyx Medical — Biotyx Medical manufactures and sells iron-based biodegradable vascular materials and stents.
Show all investments...

Hillhouse Capital Group
VC Fund · Changyang, Beijing, China · 17 investments in China Biotechnology startups, 16 in the past 12 months

Hillhouse Capital Group is an investment management firm that invests with a long-term time horizon. Hillhouse owns companies across equity stages, spanning the range from new start-ups to the world’s most established public companies. It may invest in a company as a start-up and continue to hold it in the portfolio as a public equity investment.This stage-agnostic investment style allows them to focus on multi-year results, rather than on quarterly earnings.Hillhouse Capital Group invests globally, with a particular focus on Asia. Independent, proprietary research lies at the heart of our investment process. Our team members are sector experts in consumer, Internet, media, and healthcare. Hillhouse Capital Group was founded in 2005 and is based in Beijing, China.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, India

Investor stats

  • Total investments: 312
  • Round size: Series A $1.4M–$120M; Series B $14M–$230M; Series C $14M–$310M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • Immorna — Immorna specializes in the production of RNA-based therapeutics.
  • Xingmai Innovation — Xingmai Innovation creates, develops, and sells intelligent swimming pool cleaning robots.
  • Deep Vision Intelligence — Deep Vision Intelligence is a developer of embedded machine vision products.
Show all investments...

Med-Fine Capital
VC Fund · Shanghai, Shanghai, China · 16 investments in China Biotechnology startups

Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Seed
  • Geography: China, United States

Investor stats

  • Total investments: 52
  • Round size: Seed $8M–$21M; Series A $2.7M–$20M; Series B $11M–$50M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Med-Vision — Virtual reality (VR) medical care service provider based in Hangzhou.
  • Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
  • Leadinno Medical Valley — Leadino Medical Valley is a producer of medical devices for neuroregulatory functions.
Show all investments...

Frees Fund
VC Fund · Beijing, Beijing, China · 15 investments in China Biotechnology startups, 11 in the past 12 months

By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.

Show more...

Investment focus

  • Industry: Artificial Intelligence, E-Commerce, Health Care
  • Stage:Series A, Seed, Angel
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 143
  • Round size: Seed $1.4M–$11M; Angel $412k–$5.8M; Series A $1.4M–$28M
  • Lead/follow: 24% lead, 76% follow
  • Last fund: May invest from a new fund soon — last raise in 2015

Portfolio highlights

  • Chuguang 3D — Chuguang 3D is a optical micro-nano 3D sensor technology platform that focuses on research and development, and manufacturing of micro-nano-level optical three-dimensional sensing and measurement and testing instruments.
  • Yanming Biology — Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.
  • Optical Standard Technology — Optical Standard Technology focuses on the design and manufacture of optical computing chips and optical computing boards for use in scenarios requiring large amounts of AI computing power, such as large model reasoning and training, autonomous driving, smart cities, quantitative finance, AI security.
Show all investments...

Legend Capital
VC Fund · Beijing, Beijing, China · 15 investments in China Biotechnology startups, 33 in the past 12 months

Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, South Korea

Investor stats

  • Total investments: 277
  • Round size: Series A $2.7M–$50M; Series B $11M–$110M; Series C $15M–$200M
  • Lead/follow: 42% lead, 58% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • HC Scientific — HC Scientific is a high-tech enterprise integrating research, development, production and sales of a new biomedical system
  • Saige Research — Saige Research specializes in artificial intelligence solutions for industrial inspection and quality control. The company provides a deep learning vision inspection platform optimized for the manufacturing industry to solve inspectors' difficulties and increase work efficiency; its technology provides power detection, speed detection, wideversatility, and development convenience.
  • Ligatech Bioscience — Ligatech Bioscience is an intrusive consumables developer specializing in the development and manufacture of medical devices for the field of sports medicine, as well as the development and production of biomedical materials and products. A production line for artificial ligaments and artificial ligament fixation systems has been established. Andprovide users with relevant technical advice and technical services.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Northern Light Venture Capital
VC Fund · Beijing, Beijing, China · 15 investments in China Biotechnology startups, 13 in the past 12 months

Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.

Show more...

Investment focus

  • Industry: Health Care, Medical, Internet
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, South Korea

Investor stats

  • Total investments: 202
  • Round size: Seed $500k–$16M; Series A $4M–$40M; Series B $11M–$58M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
  • Zhonghui Laser — Zhonghui Laser is an emerging technology company dedicated to the development and manufacture of advanced lasers.
  • Kangpu Biopharmaceuticals, Ltd. — Kangpu is focused on developing small molecule drugs targeting immuno-modulating sites to develop treatments for cancer, autoimmune diseases and inflammation. The company has developed proprietary technologies to generate and degrade ubiquitin-protein. It also has a drug discovery combination platform called X-Synergy®.
Show all investments...

TF Capital
VC Fund · Pudong, Shandong, China · 14 investments in China Biotechnology startups

TF Capital is a proprietary trading company that specializes in foreign exchange and invests in early stage ventures.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series A, Series B, Seed
  • Geography: China, United States

Investor stats

  • Total investments: 38
  • Round size: Seed $10M–$27M; Series A $10M–$41M; Series B $11M–$120M
  • Lead/follow: 13% lead, 87% follow

Portfolio highlights

  • UniXell — UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.
  • AskGene Pharma — AskGene Pharma is developing novel cytokine prodrugs to address critical unmet medical needs in oncology and autoimmune disease. Learn about our SmartKine platform.
  • Neowise — XinjingZhiyuan is an immune cell therapy company focusing on solid tumors.
Show all investments...

BioVenture
VC Fund · Suzhou, Jiangsu, China · 13 investments in China Biotechnology startups, 9 in the past 12 months

Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Taiwan

Investor stats

  • Total investments: 76
  • Round size: Series A $2.7M–$41M; Series B $2.7M–$55M; Series C $14M–$58M
  • Lead/follow: 49% lead, 51% follow
  • Last fund: May invest from a new fund soon — last raise in 2016

Portfolio highlights

  • Xiguang Bio — Xiguang Bio focuses on the production of diagnostic reagents and provides chemiluminescent raw materials and overall system technology solutions.
  • Jiamuyao Medical — Jiamuyao Medical specialized in developing an energy platform for the comprehensive treatment of complex intravascular lesions.
  • Panomic Biomedical Technology — Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolitepreprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.
Show all investments...

Highlight Capital
VC Fund · Nanjin, Jiangsu, China · 13 investments in China Biotechnology startups, 6 in the past 12 months

They are an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect in China and to partner with entrepreneurs with dedication and the highest standard.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Portugal

Investor stats

  • Total investments: 92
  • Round size: Series A $2.7M–$26M; Series B $2.7M–$70M; Series C $16M–$200M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • Etana — PT Etana Biotechnologies Indonesia (Etana) is an emerging producer of high-quality, affordable and innovative biopharmaceuticals to treat a range of metabolic, autoimmune and other major life-threatening diseases, including cancer. Nathan Tirtana. Legend Capital. UOB Venture Management. Innovent Bio
  • Hongyixin — Hongyixin is an automotive electronic chip developer.
  • Acchrom Tech — Huapu Instrument (Beijing) Technology Co., Ltd. is committed to building Huapu into a well-known national brand in the field of chromatography, and is an enterprise that provides the overall solution of "product + technical service" in the field of chromatography. The company formulates differentiated marketing strategies, builds anationwide marketing team centered on key provinces, and builds a professional and efficient marketing network.
Show all investments...

CDH Investments
VC Fund · Kowloon City, Kowloon, Hong Kong · 11 investments in China Biotechnology startups, 19 in the past 12 months

CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.

Show more...

Investment focus

  • Industry: Manufacturing, Biotechnology, Health Care
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Canada

Investor stats

  • Total investments: 182
  • Round size: Series A $6.9M–$233M; Series B $10M–$137M; Series C $14M–$300M
  • Lead/follow: 45% lead, 55% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Frebang — Fulibang is a novel material R&D company. Concentrate on high-end functional nanomaterial research and development, manufacture, and sales. The main products are nanofiber-based particle purification materials, antibacterial air purification materials, electrostatic melt-blown fiber filter materials with high efficiency and low resistance, gaspollutant catalytic decomposition materials, and flexible ceramic nanofiber high-temperature-resistant insulation materials.
  • Formal-Tech — Formal-Tech is an embedded system software company that specializes in the development, production, and sales of high-safety industrial control software and hardware.
  • Jianwang Technology — Jianwang Technology is a high-tech enterprise that specializes in smart energy solutions and is deeply involved in the new energy business. It focuses on the field of power electronics.
Show all investments...

CD Capital
VC Fund · Shanghai, Shanghai, China · 10 investments in China Biotechnology startups, 7 in the past 12 months

CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Series A, Series B, Angel
  • Geography: China, United States

Investor stats

  • Total investments: 51
  • Round size: Angel $412k–$14M; Series A $1.4M–$15M; Series B $6.9M–$34M
  • Lead/follow: 41% lead, 59% follow

Portfolio highlights

  • Kanova — Kanova is a biopharmaceutical firm.
  • Acchrom Tech — Huapu Instrument (Beijing) Technology Co., Ltd. is committed to building Huapu into a well-known national brand in the field of chromatography, and is an enterprise that provides the overall solution of "product + technical service" in the field of chromatography. The company formulates differentiated marketing strategies, builds anationwide marketing team centered on key provinces, and builds a professional and efficient marketing network.
  • Mol Breeding — Mol Breeding is a biotech firm that focuses on animal and plants molecular breeding technology R&D and services.
Show all investments...

Green Pine Capital Partners
VC Fund · Shenzhen, Guangdong, China · 10 investments in China Biotechnology startups, 7 in the past 12 months

Green Pine Capital Partners is a venture capital firm.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Manufacturing, Software
  • Stage:Series A, Angel, Series B
  • Geography: China, United States, Canada

Investor stats

  • Total investments: 135
  • Round size: Angel $412k–$2.1M; Series A $1.4M–$89M; Series B $9.6M–$150M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: May invest from a new fund soon — raised $137M in 2019

Portfolio highlights

  • Biodep — Biodep produces probiotics and derivatives, which are used in meals, healthy foods, cosmetics, environmental remediation, contemporary agriculture, and other industries.
  • Readline — Readline is a biological immobilized enzyme catalysis technology application service provider.
  • Guorui Xiechuang — Guorui Xiechuang is a joint venture subsidiary of Betterray New Materials Group Co., Ltd., provides power + energy storage products and system integration solutions for global customers.
Show all investments...

Addor Capital
VC Fund · Nanjing, Jiangsu, China · 10 investments in China Biotechnology startups, 48 in the past 12 months

Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.

Show more...

Investment focus

  • Industry: Manufacturing, Medical, Electronics
  • Stage:Series A, Series B
  • Geography: China, Hong Kong, United States

Investor stats

  • Total investments: 166
  • Round size: Series A $1.4M–$27M; Series B $2.7M–$41M
  • Lead/follow: 49% lead, 51% follow
  • Last fund: May invest from a new fund soon — last raise in 2021

Portfolio highlights

  • Superfuse — Superfuse specializes in R&D and production of high-performance fuse products & new generation Pyrofuse instantaneous breaker products for new energy vehicles, charging piles, wind and solar storage, two-wheeled vehicles, electric ships, data centers.
  • Aikeda Bio — Aikeda Bio provides R&D production, sales and technical services. Its products cover coagulation detection systems, specific protein detection systems, reproductive detection systems and immune detection systems
  • Matrix Software — Matrix Software is a research organization that focuses on the analysis, management, and prevention of information technology risks.
Show all investments...

Puhua Capital
VC Fund · Hangzhou, Zhejiang, China · 10 investments in China Biotechnology startups, 11 in the past 12 months

Puhua Capital is an equity investment firm that focuses on early and middle project. Puhua Capital provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Series B, Angel
  • Geography: China, United Kingdom, United States

Investor stats

  • Total investments: 114
  • Round size: Angel $412k–$8.2M; Series A $1.4M–$40M; Series B $2.7M–$69M
  • Lead/follow: 28% lead, 72% follow

Portfolio highlights

  • Zozen — Zhuzheng Robotics is a medical robot manufacturer and developer specializing in minimally invasive spinal surgery. It specializes in researching new, intelligent, high-end medical devices with independent intellectual property rights, researching and developing products related to minimally invasive spinal surgery, and providing related services.
  • Cascade — Cascade produces novel medications that target nuclear receptors for treating metabolic disorders and inflammation.
  • Zhejiang Tianneng New Material — Zhejiang Tianneng New Material manufactures batteries as well as recycles, removes, and re-uses old lithium batteries.
Show all investments...

ZhenFund
VC Fund · Beijing, Beijing, China · 9 investments in China Biotechnology startups, 12 in the past 12 months

ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. Webelieve that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Software, E-Commerce
  • Stage:Series A, Seed, Series B
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 304
  • Round size: Seed $820k–$20M; Series A $1.4M–$27M; Series B $3.4M–$50M
  • Lead/follow: 13% lead, 87% follow
  • Last fund: Likely still investing — raised $130M in 2022

Portfolio highlights

  • Mogic AI — Mogic AI is an advertising technology platform that provides tools to create and launch campaigns by pulling product images into ads using AI.
  • Levinthal — Levinthal is an AI-driven protein design platform. They offer services for artificial intelligence in food safety and medical care. They offer synthetic biology, food, feed, and environmental protection.
  • Altos Radar — Altos Radar accelerate the development and implementation of 4D Imaging Radar technology in driver-assisted and fully autonomous driving systems.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Gaorong Capital
VC Fund · Wangjing, Beijing, China · 9 investments in China Biotechnology startups, 14 in the past 12 months

Investors of Gaorong Capital include world-class sovereign wealth funds, university endowment funds, family foundations, pension funds and fund of funds, as well as successful entrepreneurs, including founders and managements of Tencent, Alibaba, Baidu, JD, Xiaomi, Focus Media and VIPShop. They will provide with valuable industry resources,entrepreneurial experience, and global perspectives.

Show more...

Investment focus

  • Industry: Software, E-Commerce, Information Technology
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 201
  • Round size: Series A $2.7M–$69M; Series B $14M–$100M; Series C $28M–$500M
  • Lead/follow: 26% lead, 74% follow
  • Last fund: May invest from a new fund soon — raised $1.2B in 2020

Portfolio highlights

  • MKSEMI — MKSEMI is a low-power ultra-wideband (UWB) company, provides a complete high precision location solution for device OEMs and ODMs.
  • Cholesgen — Cholesgen is a biopharmaceutical company dedicated to developing original innovative drugs. The company focuses on new disease targets based on biochemistry, disease biology, medicinal chemistry, and clinical translational medicine.
  • Lattice Microelectronics — Lattice Microelectronics promote the design and development, module manufacturing and vehicle application of power semiconductors.
Show all investments...

LYFE Capital
VC Fund · Shanghai, Shanghai, China · 9 investments in China Biotechnology startups, 6 in the past 12 months

In our inaugural fund, we are only seeking biotechnology, pharmaceutical, medical device, diagnostic, healthcare service and digital health companies with an established product foundation but need a bit more capital to accelerate its growth in Greater China. During this critical time, we work closely with our portfolio companies and support theirneeds not only by providing capital but with market planning, talent acquisition, global expansion and global partnership support.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, France

Investor stats

  • Total investments: 54
  • Round size: Series A $8.2M–$51M; Series B $14M–$82M; Series C $14M–$200M
  • Lead/follow: 44% lead, 56% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Noah Medical — Noah Medical is a manufacturer of medical robotic devices used to diagnose and treat patients in a variety of settings. The company's devices perform early diagnoses and treatments in advanced clinical settings, allowing hospitals to treat patients earlier and save lives while leaving only minor scars.
  • HC Scientific — HC Scientific is a high-tech enterprise integrating research, development, production and sales of a new biomedical system
  • Genepoint Biological Technology — Genepoint Biological Technology is a healthcare Company.
Show all investments...

K2VC
VC Fund · Beijing, Beijing, China · 9 investments in China Biotechnology startups, 13 in the past 12 months

K2VC (Xianfeng Evergreen) was founded in 2010, focused on early stage investment in technology start-ups in China, focus on promoting change and technological progress, innovative business models and lifestyles.

Show more...

Investment focus

  • Industry: E-Commerce, Health Care, Software
  • Stage:Series A, Angel, Seed
  • Geography: China, United States, Japan

Investor stats

  • Total investments: 135
  • Round size: Seed $1M–$12M; Angel $412k–$2.7M; Series A $1.4M–$23M
  • Lead/follow: 13% lead, 87% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • Spatomics — Spatomics is focusing on creating a cutting-edge multi-omics tool platform for single cells.
  • Aocai — Aocai is an E-commerce company that offers various items.
  • Cornerstone Robotics — Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.
Show all investments...

Cowin Capital
VC Fund · Shenzhen, Guangdong, China · 9 investments in China Biotechnology startups, 27 in the past 12 months

Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.Cowin Capital was founded in 2000 and is headquartered in Shenzhen, China.

Show more...

Investment focus

  • Industry: Manufacturing, Health Care, Software
  • Stage:Series A, Series B, Series C
  • Geography: China, Hong Kong, United States

Investor stats

  • Total investments: 168
  • Round size: Series A $4.1M–$34M; Series B $6.9M–$50M; Series C $4.1M–$100M
  • Lead/follow: 39% lead, 61% follow
  • Last fund: May invest from a new fund soon — last raise in 2014

Portfolio highlights

  • SIRUN — SIRUN is a provider and operator of Internet of Vehicles system services, alongside a manufacturer of passenger and commercial vehicles.
  • Anpaixin — Anpaixin manufactures thin-film lithium niobite photonic circuits and optical engines.
  • Xungene Therapeutics — Xunjing Biotech creates RNA-targeting small molecule medicines. The company's goal is to create RNA-targeting small molecule therapeutics that target uncommon disorders and malignancies. It employs RNA structure detection and artificial intelligence technology with its own intellectual property rights to design, screen, and evaluate smallmolecule drugs, shorten the R&D cycle in a more efficient and smarter manner, improve development efficiency, and promote faster drug marketing.
Show all investments...

EFung Capital
VC Fund · Shenzhen, Guangdong, China · 8 investments in China Biotechnology startups, 7 in the past 12 months

Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, India

Investor stats

  • Total investments: 42
  • Round size: Series A $1.4M–$76M; Series B $15M–$84M; Series C $14M–$69M
  • Lead/follow: 26% lead, 74% follow

Portfolio highlights

  • Turno — Turno Finance makes owning EV very affordable. Turno Club is a community around commercial EVs. Turno Battery Future is our solution to keeping batteries on the road for longer.
  • IASO Biotherapeutics — IASO Biotherapeutics (IASO BIO) is a Nanjing-based biopharmaceutical company focused on the discovery, development and commercialization of cell therapies in the field of oncology.
  • Huayuan Regenerative Medicine — Huayuan Regenerative Medicine is a developer of implantable biological artificial organs.
Show all investments...

Cowin Venture
VC Fund · Beijing, Beijing, China · 8 investments in China Biotechnology startups, 8 in the past 12 months

Founded in 2009, Cowin Venture is an angel and early-stage investor in TMT and Healthcare. We keep nurturing growth-stage companies graduated from their angel investment portfolio. Cowin’s business network covers China and USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing and Hong Kong.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Angel
  • Geography: China, United States, Canada

Investor stats

  • Total investments: 69
  • Round size: Angel $412k–$1.4M; Series A $1.4M–$38M; Series B $2.7M–$83M
  • Lead/follow: 22% lead, 78% follow

Portfolio highlights

  • Makino micro — Makino Micro is a high-tech enterprise dedicated to the research and development of 4D high-precision imaging radar.
  • Yimai Silicon — Yimai Silicon is a professional R&D and mass production manufacturer of advanced packaging substrate technology.
  • Gongyan Tuoxin — Gongyan Tuoxin is an optoelectronic chip design and development company that focuses on designs and supplies for high-speed optical communications and networking applications, analog and mixed-signal chips
Show all investments...

Baidu Ventures
VC Fund · Beijing, Beijing, China · 8 investments in China Biotechnology startups, 11 in the past 12 months

"BV is an independent venture fund established by Baidu in 2017. BV's investors include Baidu as well as other leading financial institutions and businesses. BV currently manages roughly $500M USD across 3 funds and has offices in Beijing and San Francisco. Its mission is to support entrepreneurs and companies who are spearheading the newage of artificial intelligence. These companies are changing the way we work and live—and ultimately how we interact."

Show more...

Investment focus

  • Industry: Artificial Intelligence, Health Care, Biotechnology
  • Stage:Series A, Seed, Series B
  • Geography: China, United States, Germany

Investor stats

  • Total investments: 151
  • Round size: Seed $1.9M–$14M; Series A $1.3M–$17M; Series B $7.3M–$64M
  • Lead/follow: 26% lead, 74% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • Sondit — Sondit specializes in R&D and manufacturing of civilian radar systems. It includes intelligent transportation, intelligent security, vehicle-road coordination, and other fields. It engaged in traffic information monitoring and urban traffic management in the field of the intelligent transportation industry.
  • Smartnvy — Smartnvy specializes in the design and development of MRAM and associated devices. Smartnvy employs an ultra-low power design platform adapted to MRAM technology, in conjunction with full-process design methodology.
  • Shengshu Technology — Shengshu Technology is an artificial intelligence solution provider that focuses on the creation of multi-modal generative big models and application products. It offers broad services to institutional businesses and technical service providers in specific industries.
Show all investments...

Source Code Capital
VC Fund · Chaoyang, Liaoning, China · 8 investments in China Biotechnology startups, 18 in the past 12 months

Founded in 2014, Source Code Capital is a leading China VC focused on the broad TMT sectors and investing in both early stage start-ups and growth stage companies. With $1.5 billion and RMB 3.5 billion under management, Source Code Capital has been successfully partnering with close to 150 leading Chinese technology founders since inceptionincluding Bytedance, Meituan, Homelink, among many others. Source Code is focused on the “Big 3” fundamental drivers, which are Internet+, AI+, and Global+ , and invests along sectors such as media and entertainment, consumer services, enterprise, finance, retail, transportation, housing, education, and healthcare.

Show more...

Investment focus

  • Industry: Software, E-Commerce, Artificial Intelligence
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, Spain

Investor stats

  • Total investments: 200
  • Round size: Series A $1.4M–$41M; Series B $14M–$90M; Series C $30M–$200M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: May invest from a new fund soon — last raise in 2021

Portfolio highlights

  • Legendsemi — Legendsemi focuses on the development and design of high-performance analog and mixed-signal chips.
  • Minghao Technology — Minghao Technology is a comprehensive solution provider for optometry.
  • Unisun Energy Group — Unisun Energy is a globalized photovoltaic technology solution provider, Unisun's eminent services rely on its effecient cost control, professional technology team, abundant project and financial resources, front-edge data analysis and reassuring O&M.
Show all investments...

Volcanics Venture
VC Fund · Changning, Shanghai, China · 8 investments in China Biotechnology startups

Volcanics Venture was founded in May 2016. They identify, invest in, and serve the most promising companies and outstanding entrepreneurs in Internet Innovation, Intelligent Technology and Healthcare industry. Managing Partners Suyang Zhang, Yeshun Dong and Ying Wu have been working closely for years as first-class USD/RMB fund managers.They have more than 60 years of aggregated VC investment and corporate management experience, as well as in-depth understanding of three focused fields. Volcanics Venture brings a powerful combination of global perspective and local experience to investment management, striving to provide sustainable value-added service to their portfolio companies and bring superior return to their limited partners.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Software
  • Stage:Series A, Series B, Seed
  • Geography: China, United States

Investor stats

  • Total investments: 84
  • Round size: Seed $350k–$14M; Series A $1.4M–$14M; Series B $5.5M–$30M
  • Lead/follow: 32% lead, 68% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • Fabrie — Fabrie develops collaboration tool for designers that has functions such as multi-person collaboration, table and diagram association, cloud storage and sharing.
  • Aiagain — Aiagain is the provider of an online WeChat management platform for WeChat sellers.
  • Fengtai Technology — Focusing on industrial information security, Fujian and Taiwan technology mainly provides professional, standard chemical control safety consulting and evaluation services to ensure information security of key industrial information infrastructure and improve security protection solutions. It mainly serves the government, industry customers, designinstitutes, research institutes, institutes, integrators and hardware and software manufacturers. Through visual, process and customized tools and methods, it helps users to carry out effective risk management and reliable operational support. .
Show all investments...

Lapam Capital
VC Fund · Beijing, Beijing, China · 8 investments in China Biotechnology startups

Lapam Capital is a healthcare-focused venture capital firm.

Show more...

Investment focus

  • Industry: Biotechnology, Pharmaceutical, Health Care
  • Stage:Series B, Series A, Series C
  • Geography: China, United States

Investor stats

  • Total investments: 26
  • Round size: Series A $12M–$20M; Series B $14M–$40M; Series C $14M–$100M
  • Lead/follow: 42% lead, 58% follow

Portfolio highlights

  • Deyun Kangrui — Deyun Kangrui is a bio-medical high-tech enterprise that integrates R&D and the production of full-chain single-cell multi-omics technology.
  • BridGene Biosciences — BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets.
  • NeuShen Therapeutics — NeuShen Therapeutics is a biotechnology company trailblazing the future treatment of neurological and psychiatric disorders.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Legend Star
VC Fund · Beijing, Beijing, China · 8 investments in China Biotechnology startups

Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance.Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem.Legend Star is the independent early-stage investment arm of LegendHoldings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Angel, Seed
  • Geography: China, United States, France

Investor stats

  • Total investments: 115
  • Round size: Seed $1.4M–$19M; Angel $412k–$6.9M; Series A $1.4M–$30M
  • Lead/follow: 22% lead, 78% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • CoJourney — CoJourney is a CDMO platform for gene therapy that combines plasmid, viral vector, and mRNA generation, analysis, and detection.
  • Carbon Energy Technology — Carbon Energy Technology develops technology for carbon utilization and its commercialization.
  • China Reserve National Energy — China Reserve National Energy is a developer of air energy storage technology. This technology has the advantages of large scale, low cost, long life, clean and pollution-free, unlimited energy storage period, independent of fossil fuels and geographical conditions, etc.
Show all investments...

Oriental Fortune Capital
VC Fund · Shenzhen, Guangdong, China · 8 investments in China Biotechnology startups, 18 in the past 12 months

Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatmentand healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.

Show more...

Investment focus

  • Industry: Software, Information Technology, E-Commerce
  • Stage:Series A, Series B, Seed
  • Geography: China, United States

Investor stats

  • Total investments: 166
  • Round size: Seed $412k–$41M; Series A $1.4M–$27M; Series B $2.7M–$100M
  • Lead/follow: 33% lead, 67% follow
  • Last fund: May invest from a new fund soon — last raise in 2015

Portfolio highlights

  • Microtreat — Microtreat specializes in the research, development, manufacturing, and sale of different high-end industrial application ultra-precision laser equipment, particularly equipment based on infrared, ultraviolet, green light, and ultra-short pulse technology, which is mostly utilized in the field of thin-film solar energy.
  • Gene Cradle — Gene Cradle is a genetic company that develops gene therapy drugs to treat rare genetic diseases as well as chronic diseases.
  • Pinfeng Medical — Pinfeng Medical is a platform firm that integrates independent research and development, manufacturing, marketing, and service to provide high-quality intelligent testing and precise diagnostic solutions to the local and international in vitro diagnostic industries.
Show all investments...

Huagai Capital
VC Fund · Beijing, Beijing, China · 8 investments in China Biotechnology startups, 9 in the past 12 months

Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Angel
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 110
  • Round size: Angel $412k–$1.3M; Series A $1.4M–$60M; Series B $3.5M–$90M
  • Lead/follow: 44% lead, 56% follow
  • Last fund: May invest from a new fund soon — raised $430M in 2018

Portfolio highlights

  • Leo Summit — Leo Summit is positioned as a provider of life science laboratory automation solutions. It provides reliable and flexible solutions for the biomedical industry, driven by the demand for automated intelligent technology in clinical medicine and drug R&D industries, and relies on artificial intelligence and motion control technology. Providesystematic intelligent products and solutions for R&D firms, AI pharmaceuticals, and CRO firms in the fields of new medications, synthetic biology, and single-cell sequencing.
  • Leaf Biotech — Leaf Biotech is a research and development, production and sales of green chemical-related materials and series intermediates. The business produces biomass resources. The focus of the research and development is the bio-based polyester material PEF and important intermediates, as well as the creation of green drugs and intermediates for healthcareproducts.
  • Dingzhi Biotech — Dingzhi Biotech specialized in immunology and animal vaccine development. It focuses on innovative and large varieties in the research of covers poultry, livestock, and pets.
Show all investments...

Prox Ventures
VC Fund · Shanghai, Shanghai, China · 7 investments in China Biotechnology startups

Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.

Show more...

Investment focus

  • Industry: Medical, Biotechnology, Health Care
  • Stage:Seed, Series A
  • Geography: China, United States, United Kingdom

Investor stats

  • Total investments: 46
  • Lead/follow: 4% lead, 96% follow

Portfolio highlights

  • VerImmune — Located in Baltimore, Maryland, VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs) that redirectspre-existing pathogenic or childhood vaccine immune memory towards tumors.
  • VacV Biotech — VacV Biotherapeutics develops an oncolytic virus platform based on the vaccinia virus. The platform genetically modifies the oncolytic virus, which improves its specificity to tumors, reduces neurotoxicity, enhances the therapeutic effect, and greatly increases the production of extracellular enveloped virus (EEV). It has higher safety andefficiency and can be administered by intravenous injection.
  • HROCT LITT Medtech — HROCT LITT Medtech has developed the unique SNP(Smart Needle Probe) needle imaging, assembled as a catheter, which OD is smaller than 1/5 of the traditional invasive OCT catheter, while the depth and resolution are all multiple times of the traditional invasive OCT catheter, achieving 1um level to supply the histopathology needed microimaging.The fiber could be compatible with different kinds of biopsy needles to access the targets, and also could be coupled with a specific laser to achieve OCT situ diagnosis and laser ablation. Its technology provides revolutionary solutions to neurosurgery, interventional pulmonology, neurovascular, nephropathy, mammary gland, cardiac, GI, and other fields.
Show all investments...

Redhill Capital
VC Fund · Guangzhou, Guangdong, China · 7 investments in China Biotechnology startups

Redhill Capital is a venture capital firm specializing in early stage investment. It primary invests in medical industry.

Show more...

Investment focus

  • Industry: Health Care, Medical, Medical Device
  • Stage:Seed, Series A
  • Geography: China

Investor stats

  • Total investments: 24
  • Round size: Seed $1.4M–$14M; Series A $2.9M–$24M
  • Lead/follow: 64% lead, 36% follow

Portfolio highlights

  • Douli — Douli is an employee service platform that provides welfare solutions for enterprises. They offer services in the fields of clothing, food, housing, transportation, medical care, entertainment, and more by combining online and offline multi-channel resources.
  • Xianwei Medical — Xianwei Medical is a manufacturer of ophthalmic surgical robots. It focuses on the field of ophthalmic surgical robots, promoting the product finalization and inspection of the third-generation ophthalmic surgical robots while also starting the medical treatment of other product pipelines under research, such as dry eye treatment equipment.
  • EnCureGen Pharmaceuticals — Huizhengqi Medicine is a pharmaceutical company that develops mRNA drugs for the treatment of tumor and immunity diseases.
Show all investments...

CASH Capital
VC Fund · Beijing, Beijing, China · 7 investments in China Biotechnology startups

CASH invests in emerging industries such as information technology and healthcare and focuses on fast-growing businesses in the start-up and growth stage.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Manufacturing
  • Stage:Series A, Series B, Series C
  • Geography: China, United States

Investor stats

  • Total investments: 71
  • Round size: Series A $1.4M–$30M; Series B $14M–$41M; Series C $4.1M–$151M
  • Lead/follow: 41% lead, 59% follow

Portfolio highlights

  • AKA Robotics — AKA Robotics developer special robots, industrial robots, intelligent equipment, and other technologies. It mainly provides professional solutions such as rust removal, cleaning, deicing, testing, spraying, and grinding for industries such as ships, petrochemicals, wind power, offshore platforms, and steel structure bridges.AKA Robotics aims tocompletely free workers from harsh working environments such as high risk and high pollution, help enterprises transform and upgrade, and achieve the goal of green development.
  • Century Yunan — Century Yunan is a new energy vehicle charging solution provider.
  • Boardstone Intelligence — Boardstone Intelligence is a provider of precision 3D inspection solutions and laboratory analysis solutions.
Show all investments...

Lucion
VC Fund · Jinan, Shandong, China · 7 investments in China Biotechnology startups, 9 in the past 12 months

Lucion is an influential professional venture capital institute.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Manufacturing
  • Stage:Series A, Seed, Series B
  • Geography: China

Investor stats

  • Total investments: 32
  • Round size: Series A $1.4M–$522M; Series B $2.7M–$21M
  • Lead/follow: 38% lead, 62% follow

Portfolio highlights

  • Best Ray — Bolui Laser is a high tech enterprises that focuses on independent research and development and industrialization of high-end lasers and laser applications. It offers clients h innovative solutions in the fields of industrial processing, cutting-edge scientific research, environmental monitoring, semiconductors, radar remote sensing, etc. andcompetitive products and advanced laser technology solutions to continue to create value for customers.
  • Tage Zhixing — Beijing Tage Zhixing Technology Co., Ltd. is a high-tech enterprise focusing on mining vehicle unmanned driving technology research, product development, and overall engineering solution design and implementation of unmanned mines. Tage Zhixing has launched a car-ground-cloud collaborative smart mine unmanned transportation system, which realizescloud intelligent dispatching management, 4G.
  • Xinhuan Technology — Xinhuan Technology specializes in advanced cardiovascular interventional, natural cavity imaging and advanced diagnostic procedures.
Show all investments...

Empower Investment
VC Fund · Shanghai, Shanghai, China · 7 investments in China Biotechnology startups

Empower Investment was founded in 2012 in Shanghai, China. Their investment covers early-stage ventures, mid-stage growth, and securities in the public market. With headquarters in Shanghai, the company established branch offices in Beijing, Shenzhen, Hangzhou and Chengdu. Empower Investment has invested in over 150 high-tech and high-growthcompanies on a global scale covering regions including China, U.S, India, South Korea, Vietnam and Hong Kong. Their portfolio companies include fast-growing industries such as internet, AI, big data, automation & robotics, financial technology, cultural creativity, advanced materials, and healthcare.The Empower team has extensive experience in both deep technologies and financial services including internet, computer science, electronic engineering, materials science, auditing and investment banking. Some team members were serial entrepreneurs. With candidness and empathy, the team is eager to find and partner with the most visionary, determined and down-to-earth entrepreneurs. It always brings great excitement and pleasure to build a bright future with them.

Show more...

Investment focus

  • Industry: Information Technology, Artificial Intelligence, Health Care
  • Stage:Angel, Series A, Seed
  • Geography: China, United States, India

Investor stats

  • Total investments: 105
  • Round size: Seed $137k–$1M; Angel $412k–$1.5M; Series A $412k–$11M
  • Lead/follow: 11% lead, 89% follow

Portfolio highlights

  • Ykccn.com — Ykccn.com is a professional company that operates and replaces the operation and maintenance of new energy vehicles.
  • Xunyuan Technology — Xunyuan Technology is a bio-refining and bio-manufacturing platform company based on non-grain carbon sources.
  • 01 Life Science and Technology — Shenzhen is a high-tech firm dedicated to the application of human micro-ecological technology to develop solutions for a healthy life. It also offers solutions for clinical research and diagnosis and treatment of diseases. It was stablished in 2016 and is based in Shenzhen, Guangdong, China.
Show all investments...

BioTrack Capital
VC Fund · Shanghai, Shanghai, China · 7 investments in China Biotechnology startups

BioTrack Capital is a China-based investment firm.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 47
  • Lead/follow: no public data

Portfolio highlights

  • Acchrom Tech — Huapu Instrument (Beijing) Technology Co., Ltd. is committed to building Huapu into a well-known national brand in the field of chromatography, and is an enterprise that provides the overall solution of "product + technical service" in the field of chromatography. The company formulates differentiated marketing strategies, builds anationwide marketing team centered on key provinces, and builds a professional and efficient marketing network.
  • Bioyond Tech — Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.
  • Qitan Technology — Developer of a genome sequencing technology. The company takes advantage of nanopores to sequence single nucleic acid molecules.Using innovative nanopore gene sequencing technology, it provides single-molecule sequencing capability with long reading length, real-time output of sequencing results, low single-running cost, small and convenientinstrument, and cost-effective gene sequencing solution without complicated library preparation. It can directly detect the apparent modification of nucleic acids and expand the application of gene sequencing technology in cutting-edge biological research and clinical medicine such as instant diagnosis, metagenomics, epigenetics, RNA and transcriptomics.
Show all investments...

Shenzhen Capital Group
VC Fund · Shenzhen, Guangdong, China · 7 investments in China Biotechnology startups, 13 in the past 12 months

Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation and emerging industriesdeveloping. SCGC has registered capital of 5.42 billion RMB, andtotal AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based of the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.

Show more...

Investment focus

  • Industry: Manufacturing, Health Care, Software
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Japan

Investor stats

  • Total investments: 241
  • Round size: Series A $1.4M–$604M; Series B $2.7M–$137M; Series C $3.9M–$137M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Cybernetics — Cybernetics is a producer of digital energy solutions and products based on electrical measuring technology.
  • Changyang Software — Changyang Software adheres to the concept of independent innovation, focuses on the field of national basic software security, develops a series of secure operating system products, and performs migration and adaptation, reconstruction, independent research and development of Xinchuang products, and security solution design and implementation.
  • Runpeng Semiconductor — Runpeng Semiconductor is a chip and integrated circuit producer and developer.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
China Growth Capital | CGC
VC Fund · Beijing, Beijing, China · 6 investments in China Biotechnology startups

China Growth Capital (CGC) is a leading early-stage venture capital firm in China with an extended interest in Silicon Valley. The firm funds seed to Series B in enterprise, technology and marketplace. The typical investment size ranges from $1M to 5M with a hard cap ceiling at $15M per company. Since its founding in 2006, China Growth Capitalhas grown to manage 8 Billion RMB (approximately 1.2 Billion USD) in asset under management across its different RMB and USD funds. Notable portfolio includes SMZDM (300785.SZ), Missfresh (NASDAQ:MF), Wish (NASDAQ:WISH), Tongdun, Tiger Brokers (NASDAQ: TIGR), BeyondHost (now part of Meituan 03690.HK), Ezbuy (NASDAQ:LITB), Cai Cloud (now part of ByteDance), PingCAP, DeePhi (now part of NASDAQ: XLNX), Airlango (now part of HKEX:03690), Nreal, Landspace, WeRide, Plus.ai, Sinovation, Singleron, 4B, ABM Therapeutics and InxMed etc.

Show more...

Investment focus

  • Industry: Software, Information Technology, E-Commerce
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 142
  • Round size: Seed $412k–$15M; Series A $1.4M–$31M; Series B $6.9M–$41M
  • Lead/follow: 37% lead, 63% follow

Portfolio highlights

  • Immorna — Immorna specializes in the production of RNA-based therapeutics.
  • Well-link — Well-link is a Chinese cloud gaming service provider.
  • Xinsheng Semiconductor — Xinsheng Semiconductor is a semiconductor and discrete device manufacturing company. They provide research, development, and sales of acoustic filters and RF front-end module products. They provide products such as filters, duplexers, multiplexers, and modules below 6 GHz. They also provide technical services.
Show all investments...

BVCF
VC Fund · Shanghai, Shanghai, China · 6 investments in China Biotechnology startups

BioVeda China Fund (BVCF) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, and Bejing

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Germany

Investor stats

  • Total investments: 18
  • Round size: Series A $6.8M–$94M; Series B $25M–$325M
  • Lead/follow: 50% lead, 50% follow
  • Last fund: May invest from a new fund soon — last raise in 2016

Portfolio highlights

  • Oculis — The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
  • Cellenkos — Cellenkos is a clinical-stage biotech company focused on the development and commercialization of transformative novel allogeneic Treg cell therapies to treat autoimmune and inflammatory disorders.
  • Drug Farm — Drug Farm is a China and US-based biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments.
Show all investments...

F-Prime Capital
VC Fund · Cambridge, Massachusetts, United States · 6 investments in China Biotechnology startups, 32 in the past 12 months

F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, China

Investor stats

  • Total investments: 308
  • Round size: Series A $5M–$63M; Series B $13M–$135M; Series C $20M–$60M
  • Lead/follow: 27% lead, 73% follow

Portfolio highlights

  • Simon Data — Simon Data is the Customer Data Platform that enables you to drive marketing results faster with a solution purpose built for growth.
  • K36 Therapeutics — K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
  • Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.
Show all investments...

Delian Capital
VC Fund · Beijing, Beijing, China · 6 investments in China Biotechnology startups

Founded in 2011, Delian Capital specializes in the field of tech-driven industry such as high-end manufacturing, cutting-edge technologies, and healthcare. Their investments range from robotics, Smart manufacturing Semiconductor, AI, big data, enterpriseservices, healthcare, etc.Examples of their investment portfolio: YueBoo、Hunan zhongli、Esafenet、Venus MedTech、MicuRx、Rokae、 IMI、12 Sigma Technologies.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Manufacturing
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, France

Investor stats

  • Total investments: 42
  • Round size: Seed $1.6M–$3.7M; Series A $1.6M–$20M; Series B $9.6M–$27M
  • Lead/follow: 31% lead, 69% follow

Portfolio highlights

  • Yaoshi Medical — Yaoshi Medical conducts research and development in the field of ocular illness diagnosis and screening equipment.
  • Qinglian Biotech — Qinglian Biotech is an innovative proteomics detection technology service provider.
  • Hunan Tree Industrial Manufacturing — Hunan Tree Industrial Manufacturing specializes in automatic robot and equipment for casting, sanding, and polishing.
Show all investments...

SDIC Venture Capital
VC Fund · Xicheng, Hebei, China · 6 investments in China Biotechnology startups, 18 in the past 12 months

ounded in 2016, SDIC Venture Capital Co., Ltd. (SDICVC) is a fund management company founded by the State Development and Investment Corp. (SDIC), under a market driven governance structure. SDICVC currently manages four funds, with total asset under management at RMB 14 Billion.SDICVC puts into practice the marketization and industrializationof the nation’s scientific and technological achievements, focusing on an investment strategy of "serving the national innovation strategy and focusing on the transformation of scientific and technological achievements". SDICVC puts its expertise and experience to work to achieve its goals of policy orientation and return on investment, faithfully implementing the national development strategy, striving to realize the synergy between the government, the society and the market, realizing its positioning as "an ideal, trustworthy, respected, influential partner” and its role as a leading professional venture fund management institution.

Show more...

Investment focus

  • Industry: Manufacturing, Biotechnology, Health Care
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 88
  • Round size: Series A $8.2M–$76M; Series B $2.7M–$275M; Series C $14M–$56M
  • Lead/follow: 47% lead, 53% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • ATOMsci — ATOMsci is a manufacturer of optoelectronic equipment that sells Raman spectrometers, photodetectors, lasers, and laser applications.
  • Yanming Biology — Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.
  • Dehui Electronics — Dehui Electronics develops, manufactures, and sells high-performance electronic ceramics and related electronic components.
Show all investments...

Linear Capital
VC Fund · Shanghai, Shanghai, China · 6 investments in China Biotechnology startups, 8 in the past 12 months

Linear Capital focuses on investment projects in the fields of Data Application, Data Infrastructure and cutting-edge technology applications. they believe that cutting-edge technology is the primary productive force, and they are committed to becoming an important promoter of cutting-edge technology landing industries, realizing FrontierTechnology,

Show more...

Investment focus

  • Industry: Biotechnology, Artificial Intelligence, Robotics
  • Stage:Seed, Series A, Angel
  • Geography: China

Investor stats

  • Total investments: 28
  • Round size: Seed $1.4M–$10M; Angel $1.4M–$5.4M; Series A $5.7M–$10M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • EYIMU — EYIMU is a provider of Professional Data Intelligence Farm Solutions that has created a precision dairy farming SaaS solution that speeds digital transformation.
  • Orthogonal — Orthogonal Technology is a leading tool vendor offering specialized software and cutting-edge hardware solutions tailored for spatial computing-based product design. Our company provides the perfect and comprehensive suite of tools to efficiently tackle all aspects of product design tasks, including form shaping, behavior modeling, andhuman-machine interaction refinement.Our feature-rich tools are designed to meet the needs of modern product design teams. With a web-based platform, users can seamlessly access and collaborate on projects from anywhere, fostering enhanced team synchronization and communication. The immersive design experience provided by our tools allows designers to step into the virtual realm, enabling them to visualize and iterate designs in a true-to-life spatial environment.Whether you're a small design studio or a large enterprise, Orthogonal Technology's software and hardware solutions offer unparalleled versatility and effectiveness to streamline your product design workflow, turning innovative ideas into tangible and market-ready products.
  • Wonsor — Wonsor focuses on automatic precision detection technology to provide professional detection solutions and chip-based products.
Show all investments...

Lotus Lake Ventures
VC Fund · Beijing, Beijing, China · 6 investments in China Biotechnology startups, 8 in the past 12 months

Lotus Lake Ventures is an investment firm committed to investing in science and technology innovation enterprises, focusing on high-tech and high-tech enterprises with core competitiveness in the initial stage and growth stage..

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series A, Series B, Series C
  • Geography: China

Investor stats

  • Total investments: 45
  • Round size: Series A $687k–$69M; Series B $2M–$37M; Series C $6M–$38M
  • Lead/follow: 18% lead, 82% follow

Portfolio highlights

  • Kanova — Kanova is a biopharmaceutical firm.
  • SinoTau — SinoTau is a total solution provider specializing in generic drugs and innovative drugs.
  • Yanming Biology — Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.
Show all investments...

Oriza Holdings
VC Fund · Suzhou, Jiangsu, China · 6 investments in China Biotechnology startups, 15 in the past 12 months

Oriza Holdings is a Chinese management fund that covers equity, debt financing, and investment since 2007.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Manufacturing
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Canada

Investor stats

  • Total investments: 125
  • Round size: Series A $1.4M–$38M; Series B $10M–$100M; Series C $19M–$300M
  • Lead/follow: 25% lead, 75% follow

Portfolio highlights

  • HIGEC — HIGEC focuses on the research and development, production, sales and after-sales service of automobile parts.
  • Guoshun Laser — Guoshun Laser is a developer of high-power ultrafast micro-nano structure fiber lasers.
  • Juxing Technology — Juxing Technology is a national high-tech firm that develops intelligent, information-based teaching and management software based on artificial intelligence and virtual reality technology.
Show all investments...

Decheng Capital
VC Fund · Menlo Park, California, United States · 6 investments in China Biotechnology startups, 6 in the past 12 months

Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. We are a group of dedicated professionals with complementary expertise who have outstanding track records of building highlysuccessful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, China, Canada

Investor stats

  • Total investments: 76
  • Round size: Series A $8M–$25M; Series B $12M–$112M; Series C $30M–$121M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: May invest from a new fund soon — last raise in 2020

Portfolio highlights

  • Adela — Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
  • Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
  • GRIT Biotechnology — GRIT Biotechnology develops tumor infiltration lymphocytes immunotherapy for solid tumors. The company was founded in 2019 and is headquartered in Shanghai, China.
Show all investments...

SBCVC
VC Fund · Shanghai, Shanghai, China · 6 investments in China Biotechnology startups

Established in 2000, SB China Capital (SBCVC) is a leading venture capital and private equity firm that manages both USD and RMB funds. Their investment focuses on high-tech, high growth companies in TMT, clean technology, healthcare, consumer/retail, and advanced manufacturing sectors; and they invest across all stages of companies.Withextensive entrepreneurial and operating experiences, their professional and seasoned deal team members recognize the vision and champion the ideas of start-up companies. In addition to providing capital support, they help their portfolio companies realize their strategic and commercial potential by giving value-adding services and advices including planning, business development, recruiting and resources deployment.They have a proven track record and solid reputation in identifying high potential start-ups and creating successful industry-leading companies. Some of their spotlight portfolio companies are Alibaba, Taobao, Focus Media, GDS, BGI, Ankon, Di’an, and Edan.With their operational headquarters located in Shanghai and regional offices spread in Beijing, Shenzhen, Chengdu, Hangzhou and Taiwan, they have an extensive coverage of the greater China region and access to potential investment opportunities.

Show more...

Investment focus

  • Industry: Health Care, Software, Information Technology
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, Australia

Investor stats

  • Total investments: 123
  • Round size: Series A $2M–$27M; Series B $4.5M–$41M; Series C $10M–$100M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • HaploX Biotechnology — HaploX Biotechnology is a Shenzhen-based genetic sequencing company.
  • Shengyin Optoelectronics — Shengyin Optoelectronics is a platform-based micro-nano manufacturing firm that creates ornamental films for electrical appliances and portable electronics.
  • Xindi Digital Engineering System — Xindi Digital Engineering System specializes in the development of 3D CAD software for manufacturing enterprises.
Show all investments...

Biotechnology VC funding in China at a glance

Stats across 1.3k deals from 1.5k investors.

1.5k
investors
in China Biotechnology startups
1.3k
deals
in China Biotechnology startups
$15M
median round
in China Biotechnology startups
35%
lead investors
lead at least one round
33%
Series A
most common funding stage

Access all 1526 VC funds in China Biotechnology startups.

Open List

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotechnology VC Funds in China investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 1526 VC funds investing in China Biotechnology startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists

Broader lists